CN115867348B - 作为il-17调节剂的咪唑并嘧啶 - Google Patents

作为il-17调节剂的咪唑并嘧啶 Download PDF

Info

Publication number
CN115867348B
CN115867348B CN202180047235.4A CN202180047235A CN115867348B CN 115867348 B CN115867348 B CN 115867348B CN 202180047235 A CN202180047235 A CN 202180047235A CN 115867348 B CN115867348 B CN 115867348B
Authority
CN
China
Prior art keywords
methyl
alkyl
pharmaceutically acceptable
acceptable salt
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180047235.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN115867348A (zh
Inventor
薛晓华
S·戈德堡
C·马丁
T·B·雷尔
V·M·坦尼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN115867348A publication Critical patent/CN115867348A/zh
Application granted granted Critical
Publication of CN115867348B publication Critical patent/CN115867348B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Fats And Perfumes (AREA)
CN202180047235.4A 2020-04-30 2021-04-28 作为il-17调节剂的咪唑并嘧啶 Active CN115867348B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063017679P 2020-04-30 2020-04-30
US63/017679 2020-04-30
PCT/IB2021/053517 WO2021220183A1 (en) 2020-04-30 2021-04-28 Imidazopyrimidines as modulators of il-17

Publications (2)

Publication Number Publication Date
CN115867348A CN115867348A (zh) 2023-03-28
CN115867348B true CN115867348B (zh) 2025-05-06

Family

ID=75769661

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180047235.4A Active CN115867348B (zh) 2020-04-30 2021-04-28 作为il-17调节剂的咪唑并嘧啶

Country Status (11)

Country Link
US (1) US12559496B2 (https=)
EP (1) EP4143193B1 (https=)
JP (1) JP7661361B2 (https=)
KR (1) KR20230018387A (https=)
CN (1) CN115867348B (https=)
AU (1) AU2021262588A1 (https=)
BR (1) BR112022021957A2 (https=)
CA (1) CA3181793A1 (https=)
IL (1) IL297734A (https=)
MX (1) MX2022013650A (https=)
WO (1) WO2021220183A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
WO2023111181A1 (en) 2021-12-16 2023-06-22 Leo Pharma A/S Small molecule modulators of il-17
WO2023166172A1 (en) 2022-03-04 2023-09-07 Leo Pharma A/S Small molecule modulators of il-17
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
CN121311483A (zh) * 2023-03-28 2026-01-09 詹森药业有限公司 含内酰胺的咪唑并哒嗪il-17抑制剂化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105992768A (zh) * 2013-12-10 2016-10-05 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
CN106715416A (zh) * 2014-09-26 2017-05-24 辉瑞大药厂 Rorc2的甲基及三氟甲基取代的吡咯并吡啶调节剂及其使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9284283B2 (en) * 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
GB201321736D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US10152431B2 (en) 2015-03-16 2018-12-11 Honeywell International Inc. System and method for remote set-up and adjustment of peripherals
US10479793B2 (en) * 2015-11-18 2019-11-19 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
GB201709456D0 (en) * 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
WO2019138017A1 (en) * 2018-01-15 2019-07-18 Ucb Biopharma Sprl Fused imidazole derivatives as il-17 modulators
WO2019223718A1 (zh) 2018-05-22 2019-11-28 成都先导药物开发股份有限公司 一种免疫调节剂
IL279348B2 (en) * 2018-06-15 2026-01-01 Reata Pharmaceuticals Inc Decahydro-2h-naphth[1,2-d]imidazole compounds for inhibition of IL-17 and ROR-gamma
JP7349491B2 (ja) * 2018-07-12 2023-09-22 ユーシービー バイオファルマ エスアールエル Ｉｌ－１７モジュレーターとしてのスピロ環状インダン類似体
KR20230019507A (ko) * 2020-04-30 2023-02-08 얀센 파마슈티카 엔.브이. Il-17의 조절제로서의 이미다조피리다진
MX2022013637A (es) 2020-04-30 2022-11-16 Janssen Pharmaceutica Nv Nuevos compuestos de triazinoindol.
MX2022013649A (es) 2020-04-30 2023-02-01 Janssen Pharmaceutica Nv Métodos para identificar moduladores de la ruta de il-17.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105992768A (zh) * 2013-12-10 2016-10-05 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
CN106715416A (zh) * 2014-09-26 2017-05-24 辉瑞大药厂 Rorc2的甲基及三氟甲基取代的吡咯并吡啶调节剂及其使用方法

Also Published As

Publication number Publication date
EP4143193A1 (en) 2023-03-08
WO2021220183A1 (en) 2021-11-04
KR20230018387A (ko) 2023-02-07
EP4143193B1 (en) 2026-04-22
IL297734A (en) 2022-12-01
CN115867348A (zh) 2023-03-28
MX2022013650A (es) 2023-02-01
JP2023523770A (ja) 2023-06-07
JP7661361B2 (ja) 2025-04-14
AU2021262588A1 (en) 2023-01-19
US20230242537A1 (en) 2023-08-03
BR112022021957A2 (pt) 2023-01-17
CA3181793A1 (en) 2021-11-04
US12559496B2 (en) 2026-02-24

Similar Documents

Publication Publication Date Title
CN115867348B (zh) 作为il-17调节剂的咪唑并嘧啶
CN115884810B (zh) 作为il-17调节剂的咪唑并哒嗪
KR102600451B1 (ko) 이미다조[1,2-b]피리다진 il-17a 억제제
JP2023106425A (ja) アミノ酸化合物および使用方法
US10961228B2 (en) JAK1 selective inhibitors
US20200352942A1 (en) Dosage forms and regimens for amino acid compounds
JP2025524640A (ja) Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
KR20220054293A (ko) Isoqc 및/또는 qc 효소의 억제제로서 n-치환된-3,4-(융합된 5-환)-5-페닐-피롤리딘-2-온 화합물
CN104892582A (zh) 作为用于治疗增生性疾病的mek抑制剂的吖丁啶
US20230028658A1 (en) Expanded dosage regimens for integrin inhibitors
KR20240082371A (ko) 이미다조피리다진 il-17 억제제 화합물
JP7159161B2 (ja) β－セクレターゼ阻害剤としてのシクロプロピル縮合チアジン誘導体および使用方法
JP2025179155A (ja) Ｓｓｔｒ４アゴニストとしてのｎ－ヘテロアリールアルキル－２－（ヘテロシクリル及びヘテロシクリルメチル）アセトアミド誘導体
US20230250070A1 (en) Dihydrooxazole and thiourea derivatives modulating the nlrp3 inflammasome pathway
CN116867781A (zh) 作为irak4抑制剂的咪唑并[1,2-a]吡啶衍生物及其在治疗疾病中的用途
WO2025153625A1 (en) Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025153624A1 (en) Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
AU2018369787B2 (en) Immunoproteasome inhibitors
CN118076606A (zh) 咪唑并哒嗪il-17抑制剂化合物
CN118317962A (zh) 咪唑并哒嗪il-17抑制剂化合物
HK40070149A (en) Dosage forms and regimens for amino acid compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant